【24h】

Heart failure biomarkers

机译:心力衰竭生物标志物

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Biomarker testing in patients with heart failure (HF) is rapidly expanding. With high-quality research indicating its diagnostic and prognostic capabilities, biomarkers are excellent adjuncts to manage patients with HF. Their superiority lies mainly in their reflection of ongoing pathophysiological events at a cellular level. Monitoring biomarker levels has been shown to provide incremental information on the progression of disease, thus allowing to better tailor treatment and management. Several biomarkers have gained attention in the past decade and continuing research demonstrates the specificity of each biomarker to be used on its own or in combination to improve diagnostic accuracy. This review will provide an insight into the role of such biomarkers, which are widely studied in the setting of HF so as to delineate their role in diagnosing, prognosticating, and titrating HF therapy.
机译:心力衰竭 (HF) 患者的生物标志物检测正在迅速扩展。高质量的研究表明其诊断和预后能力,生物标志物是治疗心衰患者的极好辅助手段。它们的优越性主要在于它们在细胞水平上反映了正在进行的病理生理事件。监测生物标志物水平已被证明可以提供有关疾病进展的增量信息,从而可以更好地定制治疗和管理。在过去十年中,几种生物标志物引起了人们的关注,持续的研究表明,每种生物标志物可以单独使用或组合使用以提高诊断准确性。本综述将深入了解这些生物标志物的作用,这些生物标志物在心衰患者中被广泛研究,以描述它们在诊断、预后和滴定心衰治疗中的作用。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号